MX348281B - Hipertension e hiperuricemia. - Google Patents
Hipertension e hiperuricemia.Info
- Publication number
- MX348281B MX348281B MX2013013655A MX2013013655A MX348281B MX 348281 B MX348281 B MX 348281B MX 2013013655 A MX2013013655 A MX 2013013655A MX 2013013655 A MX2013013655 A MX 2013013655A MX 348281 B MX348281 B MX 348281B
- Authority
- MX
- Mexico
- Prior art keywords
- subject
- serum uric
- uric acid
- acid levels
- oat4
- Prior art date
Links
- 206010020772 Hypertension Diseases 0.000 title abstract 2
- 201000001431 Hyperuricemia Diseases 0.000 title abstract 2
- 101000821902 Homo sapiens Solute carrier family 22 member 11 Proteins 0.000 abstract 3
- 102100021493 Solute carrier family 22 member 11 Human genes 0.000 abstract 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract 3
- 210000002966 serum Anatomy 0.000 abstract 3
- 229940116269 uric acid Drugs 0.000 abstract 3
- 229940121792 Thiazide diuretic Drugs 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000003451 thiazide diuretic agent Substances 0.000 abstract 2
- JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 abstract 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 abstract 1
- 201000005569 Gout Diseases 0.000 abstract 1
- CESYKOGBSMNBPD-UHFFFAOYSA-N Methyclothiazide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CCl)NC2=C1 CESYKOGBSMNBPD-UHFFFAOYSA-N 0.000 abstract 1
- CYLWJCABXYDINA-UHFFFAOYSA-N Polythiazide Polymers ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CSCC(F)(F)F)NC2=C1 CYLWJCABXYDINA-UHFFFAOYSA-N 0.000 abstract 1
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 abstract 1
- 229960003515 bendroflumethiazide Drugs 0.000 abstract 1
- HDWIHXWEUNVBIY-UHFFFAOYSA-N bendroflumethiazidum Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1=CC=CC=C1 HDWIHXWEUNVBIY-UHFFFAOYSA-N 0.000 abstract 1
- HAVZTGSQJIEKPI-UHFFFAOYSA-N benzothiadiazine Chemical compound C1=CC=C2C=NNSC2=C1 HAVZTGSQJIEKPI-UHFFFAOYSA-N 0.000 abstract 1
- 229960004064 bumetanide Drugs 0.000 abstract 1
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 abstract 1
- 229960001523 chlortalidone Drugs 0.000 abstract 1
- -1 clorothiazide Chemical compound 0.000 abstract 1
- 229960003199 etacrynic acid Drugs 0.000 abstract 1
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 abstract 1
- 229960003883 furosemide Drugs 0.000 abstract 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 abstract 1
- 229960002003 hydrochlorothiazide Drugs 0.000 abstract 1
- DMDGGSIALPNSEE-UHFFFAOYSA-N hydroflumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O DMDGGSIALPNSEE-UHFFFAOYSA-N 0.000 abstract 1
- 229960003313 hydroflumethiazide Drugs 0.000 abstract 1
- 229960004569 indapamide Drugs 0.000 abstract 1
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 abstract 1
- FGQFOYHRJSUHMR-UHFFFAOYSA-N lesinurad Chemical group OC(=O)CSC1=NN=C(Br)N1C(C1=CC=CC=C11)=CC=C1C1CC1 FGQFOYHRJSUHMR-UHFFFAOYSA-N 0.000 abstract 1
- 229960003739 methyclothiazide Drugs 0.000 abstract 1
- 229960002817 metolazone Drugs 0.000 abstract 1
- AQCHWTWZEMGIFD-UHFFFAOYSA-N metolazone Chemical compound CC1NC2=CC(Cl)=C(S(N)(=O)=O)C=C2C(=O)N1C1=CC=CC=C1C AQCHWTWZEMGIFD-UHFFFAOYSA-N 0.000 abstract 1
- 229960005483 polythiazide Drugs 0.000 abstract 1
- 229920000046 polythiazide Polymers 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229960005461 torasemide Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
- C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
- C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
- C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
- C07D285/26—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals
- C07D285/28—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
- C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
- C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
- C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Un método para el tratamiento de la hipertensión en un sujeto que lo necesite (en el que, por ejemplo, dicho tratamiento no produzca aumento en los niveles de ácido úrico en suero, niveles anormalmente elevados de ácido úrico en suero, hiperuricemia, niveles de ácido úrico en suero superiores a 6 mg/1, o el desarrollo de gota en el sujeto), comprendiendo el método administrar al sujeto: a. un diurético de tiazida; y b. un inhibidor del transportador 4 de aniones orgánicos (OAT4). El diurético de tiazida se selecciona de hidroclorotiazida, bendroflumetiazida, benzotiadiazina, hidroflumetiazida, clorotiazida, meticlotiazida, politiazida, clortalidona, metolazona, indapamida, bumetanida, ácido etacrínico, furosemida o torsemida. El inhibidor de OAT4 es ácido 2-(5-bromo-4-(4-ciclopr opilnaftalen-1-il)-4H-1,2,4-triazol-3-iltio) acético o una sal del mismo farmacéuticamente aceptable.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161489597P | 2011-05-24 | 2011-05-24 | |
| PCT/US2012/039011 WO2012162323A1 (en) | 2011-05-24 | 2012-05-22 | Hypertension and hyperuricemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013013655A MX2013013655A (es) | 2014-08-21 |
| MX348281B true MX348281B (es) | 2017-06-02 |
Family
ID=47217678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013013655A MX348281B (es) | 2011-05-24 | 2012-05-22 | Hipertension e hiperuricemia. |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20140171424A1 (es) |
| EP (1) | EP2714669B1 (es) |
| JP (1) | JP5964952B2 (es) |
| KR (1) | KR101624023B1 (es) |
| CN (1) | CN103702986A (es) |
| AU (1) | AU2012258860B2 (es) |
| BR (1) | BR112013030078A2 (es) |
| CA (1) | CA2837080C (es) |
| CY (1) | CY1119156T1 (es) |
| DK (1) | DK2714669T3 (es) |
| EA (1) | EA201370247A1 (es) |
| ES (1) | ES2633762T3 (es) |
| HR (1) | HRP20171054T1 (es) |
| HU (1) | HUE033868T2 (es) |
| IL (1) | IL229537A0 (es) |
| LT (1) | LT2714669T (es) |
| MX (1) | MX348281B (es) |
| MY (1) | MY163930A (es) |
| NZ (1) | NZ618373A (es) |
| PH (1) | PH12013502427A1 (es) |
| PL (1) | PL2714669T3 (es) |
| PT (1) | PT2714669T (es) |
| RS (1) | RS56225B1 (es) |
| SG (1) | SG195112A1 (es) |
| SI (1) | SI2714669T1 (es) |
| UA (1) | UA109943C2 (es) |
| WO (1) | WO2012162323A1 (es) |
| ZA (1) | ZA201308807B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0819847B1 (pt) | 2007-11-27 | 2022-01-11 | Ardea Biosciences, Inc | Compostos e composições |
| CA2794798C (en) | 2010-03-30 | 2017-05-30 | Ardea Biosciences, Inc. | Treatment of gout |
| CA2802407C (en) | 2010-06-15 | 2018-01-23 | Ardea Biosciences, Inc. | Treatment of gout and hyperuricemia |
| CN104311452B (zh) * | 2014-09-27 | 2016-01-06 | 张远强 | 腈基萘环的丁二酸酰胺衍生物、其制备方法及用途 |
| CN104292124B (zh) * | 2014-09-27 | 2016-01-20 | 张远强 | 硝基苯基取代的萘环丁二酸酰胺衍生物、其制备方法及用途 |
| KR102487604B1 (ko) * | 2020-11-06 | 2023-01-12 | 에스케이케미칼 주식회사 | 히드로플루메티아지드를 유효성분으로 포함하는 TNF-α 관련 질환 예방 또는 치료용 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4675586B2 (ja) * | 2004-06-23 | 2011-04-27 | 壽製薬株式会社 | 高血圧症及び血清高尿酸血症の重複発症の治療のための薬剤 |
| WO2006102069A2 (en) * | 2005-03-17 | 2006-09-28 | Microbia, Inc. | Methods and compositions for the treatment of hypertension and gastrointestinal disorders |
| BRPI0819847B1 (pt) * | 2007-11-27 | 2022-01-11 | Ardea Biosciences, Inc | Compostos e composições |
| CN102186832B (zh) * | 2008-09-04 | 2014-04-02 | 亚德生化公司 | 调节尿酸含量的化合物、组合物及其使用方法 |
| US8173690B2 (en) * | 2008-09-04 | 2012-05-08 | Ardea Biosciences, Inc. | Compounds, compositions and methods of using same for modulating uric acid levels |
-
2012
- 2012-05-22 CA CA2837080A patent/CA2837080C/en not_active Expired - Fee Related
- 2012-05-22 EP EP12789268.5A patent/EP2714669B1/en active Active
- 2012-05-22 PT PT127892685T patent/PT2714669T/pt unknown
- 2012-05-22 RS RS20170696A patent/RS56225B1/sr unknown
- 2012-05-22 SI SI201231005T patent/SI2714669T1/sl unknown
- 2012-05-22 HR HRP20171054TT patent/HRP20171054T1/hr unknown
- 2012-05-22 JP JP2014512951A patent/JP5964952B2/ja not_active Expired - Fee Related
- 2012-05-22 US US14/119,599 patent/US20140171424A1/en not_active Abandoned
- 2012-05-22 BR BR112013030078A patent/BR112013030078A2/pt not_active Application Discontinuation
- 2012-05-22 EA EA201370247A patent/EA201370247A1/ru unknown
- 2012-05-22 WO PCT/US2012/039011 patent/WO2012162323A1/en not_active Ceased
- 2012-05-22 DK DK12789268.5T patent/DK2714669T3/en active
- 2012-05-22 NZ NZ618373A patent/NZ618373A/en not_active IP Right Cessation
- 2012-05-22 MY MYPI2013004222A patent/MY163930A/en unknown
- 2012-05-22 CN CN201280036513.7A patent/CN103702986A/zh active Pending
- 2012-05-22 SG SG2013086574A patent/SG195112A1/en unknown
- 2012-05-22 PH PH1/2013/502427A patent/PH12013502427A1/en unknown
- 2012-05-22 MX MX2013013655A patent/MX348281B/es active IP Right Grant
- 2012-05-22 PL PL12789268T patent/PL2714669T3/pl unknown
- 2012-05-22 HU HUE12789268A patent/HUE033868T2/en unknown
- 2012-05-22 LT LTEP12789268.5T patent/LT2714669T/lt unknown
- 2012-05-22 UA UAA201315150A patent/UA109943C2/uk unknown
- 2012-05-22 ES ES12789268.5T patent/ES2633762T3/es active Active
- 2012-05-22 KR KR1020137034028A patent/KR101624023B1/ko not_active Expired - Fee Related
- 2012-05-22 AU AU2012258860A patent/AU2012258860B2/en not_active Ceased
-
2013
- 2013-11-21 IL IL229537A patent/IL229537A0/en unknown
- 2013-11-22 ZA ZA2013/08807A patent/ZA201308807B/en unknown
-
2017
- 2017-07-18 CY CY20171100766T patent/CY1119156T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG195112A1 (en) | Hypertension and hyperuricemia | |
| Chino et al. | ER-Phagy: quality and quantity control of the endoplasmic reticulum by autophagy | |
| Ma et al. | Design and synthesis of novel 1, 2, 3-triazole–pyrimidine–urea hybrids as potential anticancer agents | |
| Samarasinghe et al. | Heat shock factor 1 confers resistance to Hsp90 inhibitors through p62/SQSTM1 expression and promotion of autophagic flux | |
| Cravedi et al. | Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy | |
| Singh et al. | Recent advances in antifungal drug development targeting lanosterol 14α‐demethylase (CYP51): a comprehensive review with structural and molecular insights | |
| Mazumder et al. | Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells | |
| AU2020275413A1 (en) | TL1A patient selection methods, systems, and devices | |
| Chaumont et al. | Acute kidney injury in elderly patients with chronic kidney disease: Do angiotensin‐converting enzyme inhibitors carry a risk? | |
| Devasia et al. | Azole-based antibacterial agents: A review on multistep synthesis strategies and biology | |
| WO2019209942A1 (en) | Methods and systems for characterizing severe crohn's disease | |
| Tang et al. | Discovery of a novel sub-class of ROMK channel inhibitors typified by 5-(2-(4-(2-(4-(1H-Tetrazol-1-yl) phenyl) acetyl) piperazin-1-yl) ethyl) isobenzofuran-1 (3H)-one | |
| JP2014515376A5 (es) | ||
| Rocourt et al. | The catalytic subunit of DNA-dependent protein kinase is downstream of ATM and feeds forward oxidative stress in the selenium-induced senescence response | |
| Wu et al. | PR/SET domain 1 targeting glutathione peroxidase 4 regulates chronic hepatitis B liver fibrosis through ferroptosis | |
| Rodrigo et al. | Recurrence of glomerular diseases after kidney transplantation: what do we know new? | |
| Adriaenssens et al. | Mechanism of autophagy initiation by transmembrane selective autophagy receptors | |
| Kuma et al. | Selective autophagy receptors: Multifunctional regulators of organelle turnover | |
| Ha et al. | Delay of renal progression in methylmalonic acidemia using angiotensin II inhibition: a case report | |
| Van den Eynden et al. | RUVBL1 and RUVBL2 as novel druggable DNA Damage Response regulators in the N-Myc regulatory network in neuroblastoma | |
| Polzin et al. | Management of glomerulopathies | |
| Ikoma et al. | Bilateral aldosteronoma associated with secondary aldosteronism in a chronic hemodialysis subject | |
| Lehmann | Spatial regulation of the central DNA damage tolerance protein Rad5 in response to cellular stress | |
| WO2022026851A1 (en) | Targeted rna degradation allows precision repurposing of protein-targeted small molecule medicines to rna | |
| Mitsumori | Cytomegalovirus antigenaemia: 3 case reports |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |